Palonosetron

Generic Name
Palonosetron
Brand Names
Akynzeo, Aloxi, Palonosetron Accord
Drug Type
Small Molecule
Chemical Formula
C19H24N2O
CAS Number
135729-56-5
Unique Ingredient Identifier
5D06587D6R
Background

Palonosetron (INN, trade name Aloxi) is an antagonist of 5-HT3 receptors that is indicated for the prevention and treatment of chemotherapy-induced nausea and vomiting (CINV). It is the most effective of the 5-HT3 antagonists in controlling delayed CINV nausea and vomiting that appear more than 24 hours after the first dose of a course of chemotherapy and is...

Indication

For the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy, as well as prevention of acute nausea and vomiting associated with highly emetogenic cancer chemotherapy. Also used for the prevention of postoperative nausea and vomiting for up to 24 hours post operation.

Associated Conditions
Nausea caused by Chemotherapy, Post Operative Nausea and Vomiting (PONV), Acute chemotherapy-induced nausea and vomiting, Delayed chemotherapy-induced nausea and vomiting
Associated Therapies
-
Clinical Trials
Related News

Palonosetron vs Ondansetron In PONV Prophylaxis Among Idiopathic Scoliosis Patients

First Posted Date
2023-07-24
Last Posted Date
2024-12-10
Lead Sponsor
University of Malaya
Target Recruit Count
92
Registration Number
NCT05956899
Locations
🇲🇾

University Malaya, Pantai Valley, Kuala Lumpur, Malaysia

Efficacy and Safety of Intravenous Versus Oral 5-HT3 Antagonists Combined With NK-1 Receptor Antagonists for the Prevention of CINV in Breast Cancer

First Posted Date
2023-05-03
Last Posted Date
2023-05-03
Lead Sponsor
Second Affiliated Hospital, School of Medicine, Zhejiang University
Target Recruit Count
1028
Registration Number
NCT05841849
Locations
🇨🇳

the Second Affiliated Hospital of Zhejiang Univercity School of Medicine, Hanzhou, Zhejiang, China

Granisetron Transdermal Patch for Prophylaxis of Delayed CINV

First Posted Date
2021-06-03
Last Posted Date
2021-06-03
Lead Sponsor
Fudan University
Target Recruit Count
140
Registration Number
NCT04912271

Evaluate Bioequivalence of Palonosetron (0.25mg/5mL)

First Posted Date
2020-10-14
Last Posted Date
2021-08-04
Lead Sponsor
Yung Shin Pharm. Ind. Co., Ltd.
Target Recruit Count
16
Registration Number
NCT04585412
Locations
🇨🇳

Taichung Veterans General Hospital, Taichung, Taiwan

A Phase II Trial of Neoadjuvant Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) With Chemoradiation

First Posted Date
2020-03-16
Last Posted Date
2023-11-14
Lead Sponsor
Icahn School of Medicine at Mount Sinai
Target Recruit Count
29
Registration Number
NCT04308837
Locations
🇺🇸

Icahn School of Medicine at Mount Sinai, New York, New York, United States

🇺🇸

Mount Sinai St. Luke's, New York, New York, United States

🇺🇸

Mount Sinai West, New York, New York, United States

Post-Operative Nausea and Vomiting in Children Submitted to Strabismus Surgery

First Posted Date
2019-08-19
Last Posted Date
2019-08-19
Lead Sponsor
Universidade Federal Fluminense
Target Recruit Count
80
Registration Number
NCT04060771
Locations
🇧🇷

Hospital Universitário Antonio Pedro, Niterói, Rio De Janeiro, Brazil

Rolapitant Plus Olanzapine in Multiday Cisplatin Chemotherapy

First Posted Date
2019-05-22
Last Posted Date
2019-05-22
Lead Sponsor
Costantine Albany
Registration Number
NCT03960151

Cisplatin Disposition and Kidney Injury

Phase 3
Active, not recruiting
Conditions
Nephrotoxicity
Interventions
Drug: Granisetron
Drug: Ondansetron
Drug: Palonosetron
First Posted Date
2019-01-28
Last Posted Date
2024-11-21
Lead Sponsor
University of Colorado, Denver
Target Recruit Count
72
Registration Number
NCT03817970
Locations
🇺🇸

UCHealth-Metro Denver, Denver, Colorado, United States

🇺🇸

Memorial Sloan Kettering Cancer Center, New York, New York, United States

Aprepitant Triple Therapy for the Prevention of CINV in Nondrinking and Young Women Who Received Moderately Emetogenic Chemotherapy

First Posted Date
2018-09-17
Last Posted Date
2023-02-08
Lead Sponsor
Sun Yat-sen University
Target Recruit Count
248
Registration Number
NCT03674294
Locations
🇨🇳

Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China

Effectiveness and Quality of Life Analysis of Palonosetron Against Ondansetron Combined With Dexamethasone and Fosaprepitant in Prevention of Acute and Delayed Emesis Associated to Chemotherapy Moderate and Highly Emetogenic in Breast Cancer.

First Posted Date
2018-07-30
Last Posted Date
2018-07-30
Lead Sponsor
Instituto Nacional de Cancerologia de Mexico
Target Recruit Count
560
Registration Number
NCT03606369
Locations
🇲🇽

Instituto Nacional de Cancerología, Mexico City, Mexico

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy